Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06081894 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
A Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics.
- Active
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06081894 is a Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy that is active but no longer recruiting, run by Cytokinetics. The registered enrollment target is 500 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06081894, a Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, is active but no longer recruiting, sponsored by Cytokinetics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aficamten
Study Locations (20)
California
- UC San Diego Health - Sulpizio Cardiovascular Center - La Jolla
- Keck Medical Center of USC (Outpatient Clinic) - Los Angeles
- Cedars-Sinai Medical Center (Smidt Heart Institute) - Los Angeles
- UCLA Medical Center Cardiovascular Clinic - Los Angeles
- University of California San Francisco - San Francisco
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Florida
- Holy Cross Medical Group - Cardiology Associates - Fort Lauderdale
- Investigational Drug Services, AdventHealth Orlando - Orlando
Georgia
- Emory Clinic - Atlanta
- Piedmont Heart Institute (CPET) - Fayetteville
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale New Haven Hospital - New Haven
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Hawaii
- The Queen's Medical Center-Punchbowl - Honolulu
Illinois
- Northwestern University - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06081894
The ClinicalTrials.gov registry entry for NCT06081894 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06081894 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06081894 about?
NCT06081894 is a clinical study titled "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM". This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
What is the current status of trial NCT06081894?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-08-30. Estimated completion is 2026-09.
What conditions does trial NCT06081894 study?
This clinical trial studies the following conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06081894?
The interventions under investigation include: Placebo (DRUG), Aficamten (DRUG).
Who is sponsoring clinical trial NCT06081894?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06081894 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.